Theravance Biopharma (TBPH) AI Stock Analysis

• Market Cap: $766.50M
• Dividend Yield: N/A
• Average Volume (3M): 293.18K
• Price to Earnings (P/E): 65.1
• Beta (1Y): 1.01
• Revenue Growth: 24.49%
• EPS Growth: N/A
• Country: US
• Employees: 97
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.08
• Shares Outstanding: 50,361,298
• 10 Day Avg. Volume: 256,251
• 30 Day Avg. Volume: 293,181
• PEG Ratio: -0.54
• Price to Book (P/B): 2.62
• Price to Sales (P/S): 7.14
• P/FCF Ratio: -38.73
• Enterprise Value/Market Cap: 0.35
• Enterprise Value/Revenue: 3.46
• Enterprise Value/Gross Profit: 3.46
• Enterprise Value/Ebitda: 5.80
• 1Y Price Target: $20.00
• Price Target Upside: 31.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 61 Neutral
• Price Target: $16.00 ▲(5.12% Upside)

Theravance Biopharma's stock score is driven by strong technical momentum and positive earnings call highlights, indicating potential growth. However, the high P/E ratio suggests overvaluation, and financial performance shows underlying instability due to profitability challenges. Investors should weigh the strong momentum and strategic advancements against valuation concerns and financial risks.

Positive Factors

Revenue Growth

The consistent revenue growth indicates a recovery trend, suggesting the company's products are gaining market traction and acceptance, which is essential for long-term sustainability.

Cash Generation

Enhanced cash generation capabilities reflect efficient cash management, providing the company with the flexibility to invest in growth opportunities and weather financial uncertainties.

Strategic Financial Transactions

This transaction strengthens the balance sheet, providing capital for strategic investments and reducing financial risk, which supports long-term business stability.

Negative Factors

Profitability Challenges

Persistent profitability issues suggest challenges in managing operating expenses, which could hinder the company's ability to achieve sustainable financial health.

Tax Liabilities

Significant tax liabilities from recent transactions could impact cash flow and limit the company's ability to reinvest in growth initiatives.

Uncertainty in International Expansion

Uncertainty around international expansion plans could delay revenue growth from new markets, impacting the company's global market positioning.

Theravance Biopharma Business Overview & Revenue Model

Company Description

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing innovative medicines for serious illnesses, particularly in the areas of respiratory and gastrointestinal diseases. The company operates primarily in the pharmaceutical sector, with a portfolio that includes a range of products designed to address unmet medical needs. Its lead product, Vibativ (telavancin), is an injectable antibiotic used for the treatment of certain infections, and the company is actively engaged in the research and development of novel therapeutics targeting various conditions.

How the Company Makes Money

Theravance Biopharma generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, particularly Vibativ. Additionally, the company earns revenue through collaboration agreements and licensing partnerships with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on product sales. The company may also receive funding through grants and research contracts aimed at supporting its drug development initiatives. Significant partnerships with larger pharmaceutical firms can enhance its revenue potential by providing financial resources and broader market access for its products.

Theravance Biopharma Financial Statement Overview

Summary

Theravance Biopharma shows positive revenue and cash flow growth, indicating potential recovery. However, persistent profitability challenges and historical negative cash flows suggest underlying financial instability. The company needs to improve operational efficiency and profitability to enhance its financial health.

Income Statement

Theravance Biopharma shows a positive revenue growth rate of 18.29% TTM, indicating a recovery trend. However, the company struggles with profitability, as evidenced by negative EBIT and net profit margins. The gross profit margin remains strong at 100%, but the negative net profit margin suggests challenges in managing operating expenses.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.29 TTM, indicating manageable leverage. However, the negative return on equity highlights ongoing profitability issues. The equity ratio is not provided, but the overall balance sheet suggests moderate financial stability with potential risks due to negative ROE.

Cash Flow

Theravance Biopharma shows a significant improvement in free cash flow growth at 658.17% TTM, reflecting enhanced cash generation capabilities. The operating cash flow to net income ratio is positive, indicating efficient cash flow management. However, historical negative cash flows pose a risk to sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	77.20M	64.38M	57.42M	51.35M	55.31M	71.86M
Gross Profit	77.20M	64.38M	57.42M	44.76M	48.02M	-189.10M
EBITDA	46.09M	-38.45M	-42.66M	-79.86M	-249.39M	-294.00M
Net Income	13.03M	-56.42M	-55.19M	-92.82M	-199.43M	-278.02M
Balance Sheet
Total Assets	426.04M	354.16M	382.00M	607.40M	374.82M	469.06M
Cash, Cash Equivalents and Short-Term Investments	338.80M	88.35M	102.43M	327.48M	173.47M	292.94M
Total Debt	46.46M	49.82M	49.16M	74.12M	652.08M	647.06M
Total Liabilities	201.19M	178.62M	169.00M	165.60M	713.39M	772.81M
Stockholders Equity	224.85M	175.54M	213.00M	441.80M	-338.57M	-303.75M
Cash Flow
Free Cash Flow	244.78M	-11.87M	-29.48M	-187.56M	-211.26M	-257.02M
Operating Cash Flow	245.01M	-11.54M	-27.00M	-186.99M	-207.86M	-250.40M
Investing Cash Flow	-7.34M	12.28M	-32.70M	1.15B	124.49M	10.72M
Financing Cash Flow	-2.09M	-2.50M	-198.93M	-758.81M	91.86M	263.08M

Theravance Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBPH, the sentiment is Positive. The current price of 15.22 is above the 20-day moving average (MA) of 14.24, above the 50-day MA of 14.12, and above the 200-day MA of 11.12, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 69.20 is Neutral, neither overbought nor oversold. The STOCH value of 85.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBPH.

Theravance Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	―	$684.57M	―	-43.63%	―	―	-13.05%
TBPH	―	$766.50M	65.07	6.23%	―	24.49%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DAWN	―	$748.78M	―	-24.75%	―	2190.50%	52.85%
MRVI	―	$801.84M	―	-55.41%	―	-22.52%	-37.00%
TERN	―	$722.84M	―	-35.02%	―	―	20.37%
NBTX	―	$988.89M	―	―	―	―	―

Theravance Biopharma Corporate Events

Theravance Completes Enrollment in Phase 3 CYPRESS Study

On August 25, 2025, Theravance Biopharma announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). This condition affects approximately 80% of MSA patients, leading to severe symptoms like dizziness and fainting. The study aims to address the unmet need for effective nOH treatments, with topline results expected in Q1 2026. If successful, ampreloxetine could become the first therapy to provide durable benefits for the estimated 40,000 U.S. patients with MSA-related nOH, potentially transforming treatment options in this underserved market.

The most recent analyst rating on (TBPH) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Theravance Biopharma Settles Patent Dispute with Cipla

On August 15, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Cipla to resolve ongoing patent litigation over YUPELRI® inhalation solution. The agreement allows Cipla to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by U.S. authorities, while litigation continues against Mankind Pharma Ltd.

The most recent analyst rating on (TBPH) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Theravance Biopharma’s Earnings Call Highlights Strategic Gains

Theravance Biopharma’s recent earnings call painted a picture of strong financial performance and strategic maneuvers, particularly with its key products YUPELRI and TRELEGY. The company showcased its momentum and financial strength, although some uncertainties linger regarding the YUPELRI launch in China and pending tax obligations.

Theravance Biopharma Reports Strong Q2 2025 Results

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory and neurological therapies, with a notable emphasis on its FDA-approved YUPELRI® for COPD and investigational drug ampreloxetine for neurogenic orthostatic hypotension in MSA patients.